• 1
    Bronte-Stewart B, Botha MC, Krut LH. ABO blood groups in relation to ischaemic heart disease. BMJ 1962; 1: 164650.
  • 2
    Jick H, Slone D, Westerholm B, Inman WH, Versey MP, Shapiro S, Lewis GP, Worcester J. Venous thromboembolic disease and ABO blood type. Lancet 1969; 1: 53942.DOI: 10.1016/S0140-6736(69)91955-2
  • 3
    Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 1525.DOI: 10.1016/S0140-6736(95)90166-3
  • 4
    O'Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997; 77: 8258.
  • 5
    Kamphuisen PW, Eikenboom JC, Rosendaal FR, Koster T, Blann AD, Vos HL, Bertina RM. High factor VIII levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol 2001; 115: 1568.DOI: 10.1046/j.1365-2141.2001.03089.x
  • 6
    Kraaijenhagen RA, In't Anker PS, Koopman MM, Reitsma PH, Prins MH, Van Den Ende A, Büller HR. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 59.
  • 7
    Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002; 113: 63642.DOI: 10.1016/S0002-9343(02)01345-1
  • 8
    Olsson ML, Chester MA. A rapid and simple ABO genotype screening method using a novel B/O2 versus A/O2 discriminating nucleotide substitution at the ABO locus. Vox Sang 1995; 69: 2427.
  • 9
    Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19: 2513.
  • 10
    Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 15048.
  • 11
    González Ordóñez AJ, Medina Rodriguez JM, Martín L, Alvarez V, Coto E. The O blood group protects against venous thromboembolism in individuals with the factor V Leiden but not the prothrombin (factor II G20210A) mutation. Blood Coagul Fibrinolysis 1999; 10: 3037.
  • 12
    Robert A, Aillaud MF, Eschwege V, Randrianjohany A, Scarabin Y, Juhan-Vague I. ABO blood group and risk of venous thrombosis in heterozygous carriers of factor V Leiden. Thromb Haemost 2000; 83: 6301.
  • 13
    Lensen R, Bertina RM, Vandenbroucke JP, Rosendaal FR. High factor VIII levels contribute to the thrombotic risk in families with factor V Leiden. Br J Haematol 2001; 114: 3806.DOI: 10.1046/j.1365-2141.2001.02946.x
  • 14
    De Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 12716.
  • 15
    Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 14537.DOI: 10.1016/S0140-6736(94)90286-0
  • 16
    Varadi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation. Thromb Haemost 1996; 76: 2084.